We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers (BMY) Beats on Q2 Earnings, Lifts Outlook
Read MoreHide Full Article
Bristol-Myers Squibb Company’s (BMY - Free Report) second-quarter 2016 earnings of 69 cents per share beat the Zacks Consensus Estimate of 67 cents and increased 30% from the year-ago figure.
Total revenue of $4.87 billion was also above the Zacks Consensus Estimate of $4.63 billion. Reported revenues improved 17% year over year. Strong product sales drove the top line in the quarter.
Opdivo Continues to Deliver
Global revenues increased 18%, when adjusted for foreign exchange impact. Excluding Abilify and Erbitux, global revenues were up 24% or 26% adjusted for foreign exchange impact.
While sales in the U.S. markets surged 46% to $2.7 billion, international revenues were down 6%. International revenues declined primarily due to lower hepatitis C virus (HCV) sales in Japan and France. Adjusted for foreign exchange impact, international revenues were still down 4%.
Leukemia drug, Sprycel, registered sales of $451 million, up 11%. Melanoma drug, Yervoy, contributed $241 million to the top line during the reported quarter, down 19%.
Opdivo, approved for multiple cancer indications, generated revenues of $840 million, significantly higher than $704 million in the first quarter of 2016.
However, performance of key drugs in the Virology unit was disappointing. Sales of Baraclude declined 13% to $299 million. Both the Reyataz and Sustiva franchises tanked 18% and 15% to $247 million and $271 million, respectively.
Nevertheless, sales of Eliquis were $777 million during the reported quarter, up 5.9% sequentially. Bristol-Myers has a partnership with Pfizer Inc. (PFE - Free Report) for Eliquis. The HCV franchise at Bristol-Myers contributed $546 million to the company’s top line in the quarter, up 14%. Orencia revenues were up 29% to 593 million.
Adjusted research and development (R&D) expenses in the quarter increased 13.1% to $1.1 billion while marketing, selling and administrative expenses rose 9.4% to $1.2 billion.
2016 Earnings Outlook Upped Again
Bristol-Myers has raised its earnings outlook for 2016 yet again. The company now expects earnings in the range of $2.55 to $2.65 per share (old guidance: $2.50 to $2.60). The Zacks Consensus Estimate stands at $2.63 per share.
R&D expenses are now expected to increase in the mid-teen range. Previously, the company had anticipated R&D expenses to increase in the low double-digit range.
Bristol-Myers delivered another strong quarter with both the top and bottom lines beating estimates. Robust sales of drugs like Opdivo, Orencia, Eliquis and Sprycel in the reported quarter drove top-line growth. The company raised its earnings guidance once again for 2016, which is encouraging. Meanwhile, we are positive on Bristol-Myers’ efforts to develop its pipeline.
We expect investor focus to remain on updates regarding the company’s high-profile immuno-oncology drug Opdivo, going forward.
Bristol-Myers carries a Zacks Rank #2 (Buy). A couple of other favorably ranked stocks in the health care sector are Innoviva, Inc. (INVA - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Bristol-Myers (BMY) Beats on Q2 Earnings, Lifts Outlook
Bristol-Myers Squibb Company’s (BMY - Free Report) second-quarter 2016 earnings of 69 cents per share beat the Zacks Consensus Estimate of 67 cents and increased 30% from the year-ago figure.
Total revenue of $4.87 billion was also above the Zacks Consensus Estimate of $4.63 billion. Reported revenues improved 17% year over year. Strong product sales drove the top line in the quarter.
Opdivo Continues to Deliver
Global revenues increased 18%, when adjusted for foreign exchange impact. Excluding Abilify and Erbitux, global revenues were up 24% or 26% adjusted for foreign exchange impact.
While sales in the U.S. markets surged 46% to $2.7 billion, international revenues were down 6%. International revenues declined primarily due to lower hepatitis C virus (HCV) sales in Japan and France. Adjusted for foreign exchange impact, international revenues were still down 4%.
Leukemia drug, Sprycel, registered sales of $451 million, up 11%. Melanoma drug, Yervoy, contributed $241 million to the top line during the reported quarter, down 19%.
Opdivo, approved for multiple cancer indications, generated revenues of $840 million, significantly higher than $704 million in the first quarter of 2016.
However, performance of key drugs in the Virology unit was disappointing. Sales of Baraclude declined 13% to $299 million. Both the Reyataz and Sustiva franchises tanked 18% and 15% to $247 million and $271 million, respectively.
Nevertheless, sales of Eliquis were $777 million during the reported quarter, up 5.9% sequentially. Bristol-Myers has a partnership with Pfizer Inc. (PFE - Free Report) for Eliquis. The HCV franchise at Bristol-Myers contributed $546 million to the company’s top line in the quarter, up 14%. Orencia revenues were up 29% to 593 million.
Adjusted research and development (R&D) expenses in the quarter increased 13.1% to $1.1 billion while marketing, selling and administrative expenses rose 9.4% to $1.2 billion.
2016 Earnings Outlook Upped Again
Bristol-Myers has raised its earnings outlook for 2016 yet again. The company now expects earnings in the range of $2.55 to $2.65 per share (old guidance: $2.50 to $2.60). The Zacks Consensus Estimate stands at $2.63 per share.
R&D expenses are now expected to increase in the mid-teen range. Previously, the company had anticipated R&D expenses to increase in the low double-digit range.
BRISTOL-MYERS Price
BRISTOL-MYERS Price | BRISTOL-MYERS Quote
Our Take
Bristol-Myers delivered another strong quarter with both the top and bottom lines beating estimates. Robust sales of drugs like Opdivo, Orencia, Eliquis and Sprycel in the reported quarter drove top-line growth. The company raised its earnings guidance once again for 2016, which is encouraging. Meanwhile, we are positive on Bristol-Myers’ efforts to develop its pipeline.
We expect investor focus to remain on updates regarding the company’s high-profile immuno-oncology drug Opdivo, going forward.
Bristol-Myers carries a Zacks Rank #2 (Buy). A couple of other favorably ranked stocks in the health care sector are Innoviva, Inc. (INVA - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>